Celonic Group Revenue and Competitors
Estimated Revenue & Valuation
- Celonic Group's estimated annual revenue is currently $60.3M per year.
- Celonic Group's estimated revenue per employee is $155,000
Employee Data
- Celonic Group has 389 Employees.
- Celonic Group grew their employee count by -5% last year.
Celonic Group's People
Name | Title | Email/Phone |
---|
Celonic Group Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $16.1M | 104 | 28% | N/A | N/A |
#2 | $37.4M | 511 | -2% | $250.2M | N/A |
#3 | $60.3M | 389 | -5% | N/A | N/A |
#4 | $31.8M | 205 | 22% | N/A | N/A |
#5 | $1.9M | 12 | 0% | N/A | N/A |
#6 | $2.5M | 16 | -43% | N/A | N/A |
#7 | $7.9M | 51 | 2% | N/A | N/A |
#8 | $1.1M | 7 | 17% | N/A | N/A |
#9 | $0.6M | 4 | 0% | N/A | N/A |
#10 | $10.4M | 67 | 81% | N/A | N/A |
What Is Celonic Group?
Celonic Group is a privately owned CDMO with two state-of-the-art sites located at Basel (headquarters), Switzerland and Heidelberg, Germany. Providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars, worldwide, and Cell Therapy & Gene associated services worldwide. Celonic's services include the development of cell lines, production processes, as well as non-GMP and GMP manufacturing of biopharmaceutical drug substances and drug product. To complement their services with cell line development, Celonic uses its proprietary CHOvolutionâ„¢ cell line technology and the human cell line GEX® for your easy or difficult target. Being part of the JRS Pharma family, Celonic is a strong believer in creating win-win value propositions for the clients, mitigating risks by mutually-beneficial business models. Celonic is ambitious, driven by the courage to think big and the commitment to get it done. Celonic services covered: 2 INDUSTRY LEADING CELL EXPRESSION PLATFORMS: CHOvolutionâ„¢: - Powered by Celonic's proprietary SEFEXâ„¢ technology - Cell line based on CHO-K1 (non-genetically modiï¬ed CHO) - Cell line adapted to serum-free EMA and FDA compliant media - Simpliï¬ed licensing model (no royalties from sales) - High productivity (>7 g/l for mABs) GEX®: - Human cells for fully-human glycosylation - Optimized for complex and sophisticated biopharmaceutical products - Stable product quality over full run-time for R&D and/or GMP - High productivity (up to 22g/l bioreactor volume for mAbs ) PROCESS DEVELOPMENT: - State-of-art USP and DSP development - Cutting-edge, in-house, and high throughput bioanalytics - Robust and scalable BIOMANUFACTURING CAPACITIES: - Two facilities (Germany and Basel) - Up to 2,000 L capacity batches in GMP and R&D setup - In-house analytics - Swissmedic GMP certiï¬ed - 20 years of optimizing perfusion technique with >100 GMP batches FILL & FINISH: - Up to 1,250 vials/batch -Semi-automatic aseptic filling of liquids - > 300 Fill & Finish campaigns - Labeling packaging and storage of clinical test samples - Compliance with FDA & EMA standards NEW BIOLOGICAL ENTITIES : Celonic offers comprehensive approaches to enable clients to achieve commercial success, with a proven track record of developing breakthrough biologics and delivering GMP batches of ex. mABs, Growth Hormones, Fusion Proteins, and Blood Factors. BIOSIMILARS : Celonic offers ready-to-go Biosimilars (cell lines and cell pools—comprehensive analytics methods, comparability data, and development process) shaped on co-development and co-investment of next wave Biosimilars. EMPATHIE - EFFICIENCY - EXCELLENCE That's Celonic. Learn more about us.
keywords:N/AN/A
Total Funding
389
Number of Employees
$60.3M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Celonic Group News
Celonic is a premium CDMO (contract development & manufacturing organisation) for process development and production of innovative...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $109.2M | 397 | 29% | N/A |
#2 | N/A | 464 | 9% | N/A |
#3 | N/A | 623 | 21% | N/A |
#4 | $142.3M | 708 | 0% | N/A |
#5 | $35M | 1270 | 6% | N/A |